A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Launched by HANGZHOU SCIWIND BIOSCIENCES CO., LTD. · Jul 9, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different injections, called XW003 and semaglutide, to see how well they help manage obesity in Chinese adults. The goal is to find out which one works better and is safer for people struggling with obesity. Right now, the study is not yet recruiting participants.

Adults who might join this study should have a body mass index (BMI) of 30 or higher, which means they are considered obese, and a waist size of at least 90 cm for men or 85 cm for women. They should not have lost or gained more than 5% of their weight in the last three months. Certain people won’t be able to take part, including those with obesity caused by specific medical conditions, those who have had or plan to have weight-loss surgery, or those with diabetes (except for diabetes during pregnancy). Participants will receive one of the two injections to see how well it helps with weight management, and the study will monitor their safety and health throughout. This trial aims to provide more options for people dealing with obesity, helping doctors find better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.
• • Weight change of less than 5% within 3 months prior to screening (self-reported).
• Exclusion Criteria:
• • Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly.
• • History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening.
• • Diagnosis with any type of diabetes (except gestational diabetes).
• • Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening.
• • History of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).
• • History of clinically significant gastric emptying abnormalities, such as gastroparesis or gastric outlet obstruction.